Skip to main content
39°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sanofi-Aventis S.A. ADR
(NQ:
SNY
)
48.28
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,315
Open
48.28
Bid (Size)
48.63 (16)
Ask (Size)
48.65 (2)
Prev. Close
48.28
Today's Range
48.28 - 48.28
52wk Range
45.22 - 58.97
Shares Outstanding
1,250,690,553
Dividend Yield
4.22%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Big Pharma's Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System
November 20, 2024
PBMs Express Scripts, Caremark, and Optum challenge the FTC's administrative proceedings, arguing it violates constitutional rights and threatens the stability of drug pricing.
Via
Benzinga
Mutated Bird Flu Case In California Puts Humans At Increased Risk, So Which Companies Are Developing Vaccines?
November 20, 2024
According to the Los Angeles Times, the total bird flue case count in the U.S. stands at 54; 31 cases are attributed to the dairy industry.
Via
Benzinga
Performance
YTD
-3.44%
-3.44%
1 Month
-11.15%
-11.15%
3 Month
-14.20%
-14.20%
6 Month
+0.71%
+0.71%
1 Year
+1.32%
+1.32%
More News
Read More
European And US Vaccine Stocks Are Under Pressure - Here's WHy
November 15, 2024
Via
Benzinga
Exposures
Product Safety
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
November 15, 2024
Via
Benzinga
Exposures
Product Safety
Sanofi's Earnings Outlook
October 24, 2024
Via
Benzinga
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
November 15, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom
November 14, 2024
Via
Benzinga
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease
November 13, 2024
Via
Benzinga
Humanitarian Organization Criticizes Eli Lilly, Novo Nordisk And Sanofi Of Having 'Double Standards' For High Insulin Price
November 13, 2024
Via
Benzinga
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
November 08, 2024
Via
Benzinga
NASDAQ:SNY stands out as a stock that provides good value for the fundamentals it showcases.
November 07, 2024
Via
Chartmill
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
November 06, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
November 05, 2024
Via
Benzinga
FDA Panel Rejects Lexicon's Zynquista For Type 1 Diabetes
November 01, 2024
Via
Benzinga
Exposures
Product Safety
Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?
October 31, 2024
Via
Benzinga
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
October 28, 2024
Via
The Motley Fool
Why Sanofi Stock Flew Higher on Friday
October 25, 2024
Via
The Motley Fool
Sanofi (SNY) Q3 2024 Earnings Call Transcript
October 25, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
October 25, 2024
Via
Benzinga
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat
October 25, 2024
Via
Investor's Business Daily
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
October 25, 2024
Via
Benzinga
Markets Mixed Again; DECK, SKX Beat After The Bell
October 25, 2024
Via
Talk Markets
Sanofi Engages In Exclusive Talks With US Private Equity CD&R For Its Consumer Health Business
October 21, 2024
Via
Benzinga
This Vaccine Stock Just Dropped by 20%: Should You Buy the Dip?
October 21, 2024
Via
The Motley Fool
European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer
October 18, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
